Autologous tumour cell vaccine may reduce risk of tumour progression in people with primary renal cell carcinoma: Abstracted from: Jocham D, Richter A, Hoffmann L et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet 2004; 363:594–599.

Abstract

Background There is currently no evidence to support the administration of autologous renal tumour cell vaccine after radical nephrectomy for the treatment of primary renal-cell carcinoma. Objective To determine if autologous renal tumour cell vaccine given after radical nephrectomy reduces the risk of tumour progression compared with no adjuvant therapy in people with primary renal-cell carcinoma. Setting 55 institutions in Germany; recruitment from January 1997 to September 1998. Method Multicentre randomised controlled trial.